Coloplast (CPH: COLO-B) financial statements
The consolidated income statement, balance sheet and cash flow statement of Coloplast for its last 6 fiscal years, as filed with the regulator, in millions of Danish kroner. At the end of fiscal 2025 it had DKK 48,367m in total assets and DKK 16,122m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | DKK 27,874m | DKK 27,030m | DKK 24,500m | DKK 22,579m | DKK 19,426m | DKK 18,544m |
| Cost of sales | DKK 8,929m | DKK 8,761m | DKK 8,172m | DKK 7,050m | DKK 6,113m | DKK 5,932m |
| Gross profit | DKK 18,945m | DKK 18,269m | DKK 16,328m | DKK 15,529m | DKK 13,313m | DKK 12,612m |
| Operating profit | DKK 7,201m | DKK 7,320m | DKK 6,771m | DKK 6,439m | DKK 6,155m | DKK 5,854m |
| Finance costs | DKK 1,151m | DKK 1,100m | DKK 937.0m | DKK 431.0m | DKK 59.0m | DKK 408.0m |
| Profit before tax | DKK 6,157m | DKK 6,395m | DKK 6,025m | DKK 6,127m | DKK 6,233m | DKK 5,466m |
| Income tax | DKK 2,521m | DKK 1,343m | DKK 1,242m | DKK 1,421m | DKK 1,408m | DKK 1,269m |
| Net profit | DKK 3,636m | DKK 5,052m | DKK 4,783m | DKK 4,706m | DKK 4,825m | DKK 4,197m |
| Earnings per share | DKK 16.13 | DKK 22.46 | DKK 22.21 | DKK 22.14 | DKK 22.67 | DKK 19.74 |
| Diluted earnings per share | DKK 16.13 | DKK 22.46 | DKK 22.20 | DKK 22.11 | DKK 22.63 | DKK 19.67 |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total assets | DKK 48,367m | DKK 48,073m | DKK 48,159m | DKK 37,446m | DKK 15,841m | DKK 13,499m |
| Current assets | DKK 10,453m | DKK 10,444m | DKK 9,937m | DKK 8,772m | DKK 6,994m | DKK 6,489m |
| Inventories | DKK 3,919m | DKK 3,672m | DKK 3,522m | DKK 3,187m | DKK 2,428m | DKK 2,227m |
| Property, plant and equipment | DKK 6,201m | DKK 5,649m | DKK 5,131m | DKK 4,474m | DKK 3,785m | DKK 3,311m |
| Cash | DKK 947.0m | DKK 788.0m | DKK 911.0m | DKK 414.0m | DKK 448.0m | DKK 323.0m |
| Current liabilities | DKK 6,505m | DKK 10,204m | DKK 16,311m | DKK 7,336m | DKK 6,314m | DKK 4,979m |
| Equity | DKK 16,122m | DKK 17,942m | DKK 17,299m | DKK 8,292m | DKK 8,168m | DKK 7,406m |
| Equity including minorities | DKK 16,122m | DKK 17,942m | DKK 17,299m | DKK 8,292m | DKK 8,168m | DKK 7,406m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | DKK 6,645m | DKK 2,766m | DKK 4,226m | DKK 5,099m | DKK 5,290m | DKK 4,759m |
| Investing cash flow | −DKK 1,251m | −DKK 1,336m | −DKK 8,957m | −DKK 11,759m | −DKK 2,011m | −DKK 901.0m |
| Financing cash flow | −DKK 5,187m | −DKK 1,518m | DKK 5,265m | DKK 6,591m | −DKK 3,176m | −DKK 3,857m |
| Dividends paid | DKK 4,958m | DKK 4,720m | DKK 4,247m | DKK 4,041m | DKK 3,830m | DKK 3,612m |
Where each figure comes from
From the annual report Coloplast files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Coloplast page.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.